NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta
- Conditions
- Cervical Intraepithelial Neoplasia
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 664
- Registration Number
- NCT00443313
- Locations
- 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
- Conditions
- Recurrent Colon CancerExtensive Stage Small Cell Lung CancerStage III Pancreatic CancerRecurrent Rectal CancerStage II Pancreatic CancerLimited Stage Small Cell Lung CancerStage IVB Pancreatic CancerStage III Rectal CancerRecurrent Pancreatic CancerStage I Pancreatic Cancer
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019006
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Exercise Amenorrhea Stress and Bone Health in Adolescents
- Conditions
- Healthy
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis
- Conditions
- End-Stage Renal DiseaseDialysisHemodialysis
- Interventions
- Dietary Supplement: N-acetylcysteineDietary Supplement: placebo
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2010-03-03
- Target Recruit Count
- 30
- Registration Number
- NCT00440869
- Locations
- 🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
- Conditions
- Adenocarcinoma of the ProstateStage II Prostate Cancer
- Interventions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 204
- Registration Number
- NCT00438464
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Family-Centered Diabetes Project - Sharing Wisdom
- Conditions
- PrediabetesMetabolic SyndromeOverweightObesity
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 200
- Registration Number
- NCT00438126
- Locations
- 🇺🇸
University of New Mexico School of Medicine, Albuquerque, New Mexico, United States
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube CancerMalignant Tumor of PeritoneumRecurrent Ovarian Epithelial Cancer
- Interventions
- Biological: ziv-afliberceptOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00436501
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
- Conditions
- Recurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00436605
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
- Conditions
- Ovarian NeoplasmFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00436215
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Aflibercept for Relapsed Multiple Myeloma
- Conditions
- Stage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- Biological: aflibercept
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT00437034
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States